BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology

Contributed by: PR Newswire

Tags

BIOARCTIC-Lilly-colab

More Like This

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

BioArctic and Eisai sign research evaluation agreement regarding BAN2802

BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program

BrainTransporter™ dramatically improves antibody delivery to the brain

BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing

BioArctic's founders intend to divest minor part of their shareholding

BioArctic's Capital Markets Day 2025 - entering a new era of growth

Interim Report for the period July - September 2025: BioArctic